Channa Debruyne

Channa has more than 25-year experience in clinical development of chemotherapeutic products and immunotherapeutic vaccines. She led clinical team for the GSK MAGE-A3 Cancer Immunotherapeutic registration trials. She had a successful career at EORTC (European Organisation for Research and Treatment of Cancer), EMA (European Medicines Agency), GSK Vaccins and University Hospital Leuven.